Cancer development risk assessment device, program, and method for testing cancer development risk

Patent metadata

Field	Value
Publication number	US-2018275131-A1
Application number	US-201615764176-A
Country	US
Kind code	A1
Filing date	Sep 28, 2016
Priority date	Sep 29, 2015
Publication date	Sep 27, 2018
Grant date	—

Abstract

Provided is a cancer development risk assessment device ( 1 ) capable of determining the possibility of cancer development in a subject to be assessed in short time. The cancer development risk assessment device ( 1 ) includes a measurement unit ( 3 ) and a controller ( 4 ). The measurement unit ( 3 ) is configured to measure concentrations of a plurality of types of target components included in exhaled air collected from a subject to be assessed. The controller ( 4 ) is configured to calculate an assessment score correlated to the possibility of cancer being developed in the subject to be assessed based on measurement results of the concentrations obtained by the measurement unit ( 3 ).

First claim

1 - 18 . (canceled)

19 . A cancer development risk assessment device, comprising:
a measurement unit configured to measure concentrations of a plurality of types of target components included in exhaled air collected from a subject to be assessed; and a controller configured to calculate an assessment score correlated to the possibility of cancer being developed in the subject to be assessed based on measurement results of the concentrations obtained by the measurement unit, the plurality of types of target components comprising at least two types of components selected from the group consisting of 1-methylpyrrolidine, 2-methyl-propionic acid, benzaldehyde, acetic acid, butyric acid, trimethylamine, 1-octen-3-ol, mercaptoacetone, acetophenone, acetoin, carbon disulfide, 2-methyl-butyric acid, 6-methyl-5-hepten-2-one, decanal, propionic acid, heptanal, 2-methylfuran, 2,3-butanedione, nonanal, methyl mercaptan, dimethyl sulfide, and dimethyl trisulfide.

20 . The cancer development risk assessment device according to claim 19 , wherein
the plurality of types of target components further comprise at least one type of component selected from the group consisting of phenol, butanal, and hexanoic acid.

21 . The cancer development risk assessment device according to claim 19 , wherein
the controller is configured to standardize the measurement results of the concentrations to calculate a plurality of standardized values and then calculate the assessment score based on results obtained by comparing measurement results of the standardized values to thresholds respectively set for the plurality of types of target components.

22 . The cancer development risk assessment device according to claim 19 , wherein
the controller is configured to standardize the measurement results of the concentrations to calculate a plurality of standardized values and then calculate the assessment score based on the plurality of standardized values and levels of contribution of the plurality of standardized values.

23 . The cancer development risk assessment device according to claim 19 , wherein
the controller is configured to standardize the measurement results of the concentrations to calculate a plurality of standardized values and then calculate the assessment score based on the plurality of standardized values, levels of contribution of the plurality of standardized values, combination of two or more of the plurality of standardized values, and a level of contribution of the combination.

24 . The cancer development risk assessment device according to claim 19 , wherein
the controller is configured to calculate the assessment score using the following formula (3),

S
=

∑

i
=
1

n





A
i

×

α
i

(
3
)

where n is the number of types of target components, A i is the standardized value of an i(th) target component, α i is a level of contribution of the standardized value of the i(th) target component, and S is the assessment score.

25 . A cancer development risk assessment device, comprising:
a measurement unit configured to measure concentrations of a plurality of types of target components included in exhaled air collected from a subject to be assessed; and a controller configured to calculate an assessment score correlated to the possibility of cancer being developed in the subject to be assessed based on measurement results of the concentrations obtained by the measurement unit, the plurality of types of target components comprising at least two types of components selected from the group consisting of benzaldehyde, heptanal, acetic acid, 2-methyl-butyric acid, 6-methyl-5-hepten-2-one, 2-methyl-propionic acid, decanal, butyric acid, 1-octen-3-ol, 2-methyl-1-propanol, acetoin, propionic acid, 2,3-butanedione, mercaptoacetone, trimethylamine, acetophenone, cyclohexanone, 1,2-ethanediol, 1-pentanol, 1-butanol, 4-ethylcyclohexanol, nitrosomethylurethane, 2,2,4-trimethylhexane, 2,4-bis(1,1-dimethylethyl)-phenol, 3-methyl-1-butanol, 2,4-dimethylheptane, 1-octene, 2-methylfuran, nonanal, butylbenzene, β-phellandrene, 2-propenal, D-limonene, 1-methoxy-2-propanol, octanal, and 1,3-dichlorobenzene.

26 . The cancer development risk assessment device according to claim 25 , wherein
the plurality of types of target components comprise at least one type of component selected from the group consisting of phenol, butanal, 1-heptanol, 1-propanol, 2-butanone, decane, dodecane, n-hexane, nonane, ethylacetate, and o-xylene.

27 . The cancer development risk assessment device according to claim 25 , wherein
the controller is configured to standardize the measurement results of the concentrations to calculate a plurality of standardized values and then calculate the assessment score based on results obtained by comparing measurement results of the standardized values to thresholds respectively set for the plurality of types of target components.

28 . The cancer development risk assessment device according to claim 25 , wherein
the controller is configured to standardize the measurement results of the concentrations to calculate a plurality of standardized values and then calculate the assessment score based on the plurality of standardized values and levels of contribution of the plurality of standardized values.

29 . The cancer development risk assessment device according to claim 25 , wherein
the controller is configured to standardize the measurement results of the concentrations to calculate a plurality of standardized values and then calculate the assessment score based on the plurality of standardized values, levels of contribution of the plurality of standardized values, combination of two or more of the plurality of standardized values, and a level of contribution of the combination.

30 . The cancer development risk assessment device according to claim 25 , wherein
the controller is configured to calculate the assessment score using the following formula (3),

S
=

∑

i
=
1

n





A
i

Assignees

• Nissha Co Ltd
• Univ Kyoto

Inventors

• Hanada Mariko
• Koda Hiroshi
• Komura Hajime
• Morimoto Satoshi
• Tokuno Katsumi
• Tanaka Katsuyuki
• Ashida Noriko
• Kodama Yuzo
• Chiba Tsutomu
• Mima Atsushi
• Takada Masahiro
• Toi Masakazu

Classifications

• G01N33/575 Primary

  for cancer · CPC title

• G01N33/5758 Primary

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/48

  Biological material, e.g. blood, urine (G01N33/02, G01N33/26, G01N33/44, G01N33/46 take precedence); Haemocytometers (counting blood corpuscules distributed over a surface by scanning the surface G06M11/02) · CPC title

• G01N33/497

  of gaseous biological material, e.g. breath · CPC title

• G01N33/57484 Primary

  Physics · mapped topic